In January 2016, Dr. Uettwiller-Geiger was selected to lead the Choosing Wisely initiative, which promotes a national dialogue on receiving treatment that is truly necessary, not a duplicate of other tests, supported by evidence, and free of patient harm. She has offered critical contributions ever since, from preparing presentations to reviewing evidence-based guidelines to educating clinicians on test utilization.
Dr. Uettwiller-Geiger has been widely recognized for her achievements. In 2010, she received the National Academy of Clinical Biochemistry Distinguished Abstract Award, the AACC Management Sciences Abstract Award for Outstanding Project, and the Brookhaven’s Women’s Recognition Award for Science. In 2015, she received the ICE Award (Increasing Clinical Effectiveness) from the Clinical Laboratory Management Association for her efforts to decrease HAIs.1
Dr. Uettwiller-Geiger has also authored over 80 peer-reviewed articles, many of which involve work she conducted as a Principal Investigator (PI), where she has assisted several in-vitro diagnostic manufacturers of varying sizes with clinical trials. Her FDA-reviewed contributions have helped bring new advancements to market and new hope to patients.
The results of Denise Uettwiller-Geiger’s dedication to clinical laboratory science have been both an inspiration and an innovation. Cardinal Health is honored to recognize her as a urEssential finalist for 2018.